Recent Updates
Recently added Catalysts

Atossa Therapeutics, Inc.

ATOSFDA catalysts, PDUFA dates & pipeline intelligence
$1.9
▼ -0.03 · -1.55%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ATOS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.7052W HIGH $14.85
Volume
46.52 K
Value Traded
88.24 K
Short % Float
5.36%
Days to Cover
7.6
-6.4%Week
-25.78%1 Month
-28.03%3 Month
-60.74%6 Month
-89.86%5 Year
-99.96%All Time

Cash Data

Unlock ATOS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
18.96 M
EPS (TTM)
-3.47
P/E Ratio
-
Ent. Value
-1.61 M
Total Shares
9.98 M
Float Shares
9.83 M
Insiders
1.52%
Institutions
12.27%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
(Z)-endoxifen
breast cancer
Phase 2Small MoleculesOncology
Unlock every ATOS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ATOS Catalyst Timeline

Dated clinical, regulatory and corporate events for Atossa Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Atossa Therapeutics, Inc.

641Total events
11Upcoming
93Tier-1 (high impact)
2014 to 2036Coverage

Upcoming catalysts 2

T1NDA Submission
Subscribe to view catalyst details
endoxifen
T2Oral Presentation
Subscribe to view catalyst details
endoxifen

Event history 50

●Quarterly UpdateCorporate
Third Quarter 2026 financial results reported
●Stock ListingCorporate
Atossa common stock begins trading with stapled CVRs
●Partnership / LicenseCorporate
Definitive Stapled Contingent Value Rights Agreement executed with VStock Transfer, LLC
●Corporate ApprovalCorporate
Board of Directors declared dividend of one stapled CVR per share
▲Partnership / LicenseCorporate
Stapled Contingent Value Rights Agreement tied to first PRV monetization
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
▲Preclinical PoCPreclinical
Publication of preclinical study of novel (Z)-endoxifen-related compounds in npj Breast Cancer
ER-positive breast cancersource ↗
▲PublicationPresentation
Publication of novel (Z)-endoxifen-related compounds in npj Breast Cancer
ER-positive breast cancersource ↗
●Poster PresentationendoxifenPresentation
Poster presentation of (Z)-Endoxifen preclinical data in MAS-PPP at AACR Special Conference on Rare Cancers
McCune-Albright Syndrome-associated Peripheral Precocious Puberty (MAS-PPP)source ↗
▲Enrollment CompleteendoxifenTrial
Enrollment completed in EVANGELINE Phase 2 study
Breast Cancersource ↗
Unlock the full ATOS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ATOS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-12-31Z-endoxifen Phase 2 data readout Phase 2
Unlock 4 more ATOS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 53%
Micro Cap
(rank 385 of 725)
Percentile Rank
Showing 4 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
endoxifen Small MoleculesNCT07869732Precocious Puberty, Gonadotropin-dependentPhase 2 NOT YET_RECRUITING 6Sep 1, 2028
endoxifen Small MoleculesNCT05607004Breast NeoplasmsPhase 2 ACTIVE NOT_RECRUITING 87Apr 1, 2027
endoxifen Small MoleculesCompletedNCT04616430Mammographic Breast DensityPhase 2 COMPLETED 90Sep 4, 2019
Z-Endoxifen Small MoleculesCompletedNCT05068388Breast DensityPhase 2 COMPLETED 240Mar 12, 2026
Unlock the ATOS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ATOS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Endoxifen
OrphanRare Pediatric
breast cancer risk reductionPhase 22026-05-061 mg dose reduced MBD by 19.3% versus placebo (p=0.004); 2 mg dose reduced MBD by 26.5% (p<0.001)Read MoreAtossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal WomenRead More
Scroll for more · summaries link to the source press release
Unlock every ATOS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ATOS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Steinhart Richard IDirectorGrant/Award 10,000 10,000 held$0.00 05/12/2026
Unlock the full ATOS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in ATOS for Q3 2026.
Unlock every fund holding ATOS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ATOS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ATOS ownership
Insider and institutional ownership, quarter by quarter.

ATOS Short Interest

Shares sold short, counted twice a month.

5.36%
Short % of Float
of tradable shares sold short
526.8K
Shares Sold Short
-22.9% vs prior count
7.6 High
Days to Cover
trading days of normal volume to buy every short share back
69.4K
Avg Daily Volume
the average used for days to cover
Unlock ATOS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock ATOS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ATOS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ATOS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ATOS ranks across every disease it competes in

Competitive Position is a premium feature
See how ATOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ATOS News

ATOS
Nov 10, 2026
ATOSGeneral

Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics reported its third quarter 2026 financial results, highlighting a new contingent value rights agreement for shareholders. The company anticipates FDA clearance for its IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome by early 2027. Additionally, results from the Karisma trial will be presented at the San Antonio Breast Cancer Symposium in December.

Read more →
ATOS
Oct 19, 2026
ATOSGeneral
▼ -12%on this news

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Atossa Therapeutics announced that each outstanding share of its common stock will begin trading with a stapled contingent value right (CVR) effective October 19, 2026. This initiative aims to provide shareholders with a contractual opportunity to benefit from the potential value of Atossa's first qualifying priority review voucher. The CVRs will remain attached to the shares unless detached by the Board, and they will not trade separately. Atossa has received FDA designations for its product candidate, (Z)-endoxifen, but no product has been approved yet.

Read more →
ATOS
Oct 9, 2026
ATOSGeneral

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Atossa Therapeutics has executed a Stapled Contingent Value Rights Agreement, granting shareholders a right to 25% of net proceeds from the sale of its first qualifying priority review voucher (PRV), capped at $50 million. Each share of common stock outstanding as of October 19, 2026, will receive one CVR. The agreement aims to enhance shareholder value while allowing Atossa to maintain strategic flexibility in its development programs.

Read more →
ATOS
Sep 29, 2026
ATOSGeneral

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Atossa Therapeutics plans to issue contingent value rights (CVRs) to shareholders, allowing them to benefit from the potential monetization of a priority review voucher related to its rare pediatric disease programs. Each CVR will entitle holders to 25% of net proceeds from the voucher, subject to a $50 million cap. However, no product has been approved yet, and the CVRs are contingent on future developments.

Read more →
ATOS
Sep 24, 2026
ATOSConferences/Events
▼ -6%on this newsshared move

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Atossa Therapeutics CEO Dr. Steven Quay will join a panel at the ARDD 2026 to discuss the translation of scientific evidence in aging into clinical trials and regulatory pathways. The event, taking place at Harvard University, aims to explore innovative approaches to drug development for age-related diseases. Dr. Quay emphasizes the importance of strong biological evidence in clinical trial design.

Read more →
ATOS
Aug 7, 2026
ATOSGeneral

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics reported its financial results for Q2 2026, highlighting progress in developing (Z)-endoxifen for rare diseases and breast cancer. The company presented new data at major conferences, reinforcing the drug's potential. Despite a net loss of $8.5 million and increased operating expenses, Atossa secured additional funding through a registered direct offering.

Read more →
ATOS
Jul 28, 2026
ATOSPhases

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Atossa Therapeutics announced the publication of a study identifying five novel (Z)-endoxifen-related compounds that exhibit potent anti-cancer activity in estrogen receptor-positive breast cancer models. The compounds showed promising results, particularly in combination with abemaciclib, and in models with ESR1 mutations. Further evaluation of these compounds is warranted, although current findings are preclinical and do not confirm safety or efficacy in patients.

Read more →
ATOS
Jul 21, 2026
ATOSConferences/Events

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics presented data on (Z)-endoxifen at the AACR Special Conference, showcasing its dual mechanism of action for treating McCune-Albright Syndrome. The findings suggest that (Z)-endoxifen could effectively modulate estrogen receptor signaling and associated pathways, addressing significant therapeutic gaps in managing estrogen-driven conditions. This research supports further exploration of (Z)-endoxifen as a targeted treatment option.

Read more →
ATOS
Jun 12, 2026
ATOSGeneral

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics has successfully closed a registered direct offering, raising $4.5 million in gross proceeds. The offering includes Series A and Series B warrants, which could potentially yield an additional $12 million if fully exercised. The funds will be allocated towards clinical development and general corporate purposes. The company emphasizes that there are no guarantees regarding the exercise of the warrants.

Read more →
ATOS
Jun 11, 2026
ATOSGeneral
▼ -41.3%on this newsshared move

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics has announced a registered direct offering to raise up to $16.5 million, consisting of $4.5 million upfront and potential additional proceeds from warrants. The offering is aimed at funding clinical development and general corporate purposes. The closing is expected around June 12, 2026, pending customary conditions.

Read more →
ATOS
May 27, 2026
ATOSPhases

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Atossa Therapeutics announced the acceptance of two abstracts for presentation at the ASCO 2026 Annual Meeting, highlighting the efficacy of (Z)-endoxifen in treating ER-positive breast cancer with ESR1 mutations. Preclinical results indicated significant estrogen receptor inhibition, suggesting (Z)-endoxifen's potential role in overcoming endocrine resistance. Additionally, the ongoing EVANGELINE Phase 2 trial is evaluating its effectiveness combined with goserelin as neoadjuvant therapy for premenopausal women. This research underscores Atossa's commitment to addressing important treatment gaps in breast cancer care.

Read more →
ATOS
May 20, 2026
ATOSGeneral

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics announced the acceptance of a manuscript detailing the potential of (Z)-endoxifen to modulate utrophin pathways in Duchenne Muscular Dystrophy (DMD). The review highlights how (Z)-endoxifen may support muscle stabilization and repair. The company plans further preclinical evaluations and biomarker development to explore its therapeutic potential.

Read more →
ATOS
May 14, 2026
ATOSConferences/Events

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Atossa Therapeutics will host a virtual event featuring Dr. Laura Esserman to discuss the development of (Z)-endoxifen for ER-positive breast cancer. The event will cover recent clinical data, including the I-SPY2 study and biomarker findings. Dr. Esserman, a leader in breast cancer research, will provide insights into the therapy's potential as an endocrine treatment across various settings.

Read more →
ATOS
May 8, 2026
ATOSFDA Updates

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics reported its financial results for Q1 2026, highlighting progress in the development of (Z)-endoxifen for breast cancer and rare diseases. The company received FDA designations for its drug in Duchenne Muscular Dystrophy and McCune-Albright Syndrome. Despite a strong balance sheet, operating expenses and net losses have increased compared to the previous year.

Read more →
ATOS
May 6, 2026
ATOSPhases

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

Atossa Therapeutics announced the publication of the KARISMA Endoxifen trial results, which demonstrated that low-dose Endoxifen significantly reduces mammographic breast density in healthy premenopausal women. The Phase 2 study showed reductions comparable to tamoxifen, with a favorable tolerability profile. The findings suggest Endoxifen could be a promising option for breast cancer risk reduction.

Read more →
ATOS
May 4, 2026
ATOSFDA Updates
▲ +9.9%on this newsshared move

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Atossa Therapeutics has received FDA Rare Pediatric Disease designation for (Z)-endoxifen, aimed at treating McCune-Albright Syndrome in females. This designation not only validates the drug's potential beyond oncology but also opens up opportunities for a Priority Review Voucher upon approval. The company emphasizes its commitment to addressing the significant unmet medical needs associated with this rare pediatric disorder.

Read more →
ATOS
Mar 25, 2026
ATOSGeneral
▼ -13.1%on this newsshared move

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics reported total operating expenses of $37.1 million for the year ended December 31, 2025. This amount represents an increase of $9.5 million from the prior year total of $27.6 million. The company also announced that it received FDA Rare Pediatric Disease and Orphan Drug designations for its drug candidate, (Z)-endoxifen, in the treatment of Duchenne Muscular Dystrophy.

Read more →
ATOS
Mar 19, 2026
ATOSGeneral

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Atossa Therapeutics has announced the addition of Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. to its clinical leadership team. Dr. Theall will serve as Medical Director for Breast Oncology while Dr. Giwa will take on the role of Medical Director for Rare Diseases. Both executives bring extensive experience from their respective fields, which is expected to enhance Atossa's clinical development strategy for its lead product, (Z)-endoxifen, across various therapeutic areas. The company aims to meet key clinical and regulatory milestones with this strengthened team.

Read more →
ATOS
Mar 12, 2026
ATOSPhases
▲ +5.6%on this news

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Atossa Therapeutics presented promising findings on (Z)-endoxifen at the MDA Clinical & Scientific Conference. The preclinical study indicates that (Z)-endoxifen may restore muscle performance and reduce damage biomarkers in dystrophic mice, suggesting its potential as a new treatment for Duchenne muscular dystrophy. The company emphasizes the need for further clinical investigation.

Read more →
ATOS
Feb 11, 2026
ATOSGeneral
▼ -16%on this news

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics paused its metastatic breast cancer program to focus on other oncology and rare disease opportunities. The company received Rare Pediatric Disease and Orphan Drug Designations for (Z)-endoxifen in Duchenne Muscular Dystrophy. Preliminary data showed the drug reduced tumor activity markers in a small breast cancer pilot study. These moves aim to strengthen the firm's pipeline and intellectual property position.

Read more →

About Atossa Therapeutics, Inc.

Seattle, WA 14 employees atossatherapeutics.com
Headquarters1448 NW MARKET STREET, SEATTLE, WA, 98107
Founded2008
BIOPHARMAWATCH ELITE
Trade the next ATOS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime